Tirzepatide
Symbol Tz · MW 4814 Da
Dual GIP and GLP-1 receptor agonist with potent metabolic effects.
- Discovered
- 2016
- Half-life
- 5 days
- Approval
- FDA-approved (Mounjaro, Zepbound)
Reported effects
- Powerful weight loss
- A1c reduction
- Lipid improvement
Overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide used for type 2 diabetes management and chronic weight management. By targeting two incretin hormone pathways, Tirzepatide helps regulate appetite, insulin response, blood sugar control, and metabolic function. It supports weight loss by helping users feel full, reducing hunger, and improving how the body responds to food intake. Tirzepatide is often discussed as one of the most powerful modern weight loss peptides because of its dual-action mechanism. Its purpose is not simply fat burning, but broader metabolic support through appetite regulation, glucose control, and improved energy balance.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 2.5–15 mg
- Typical Frequency
- Once weekly
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Tirzepatide?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.